336 related articles for article (PubMed ID: 26851606)
21. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
[No Abstract] [Full Text] [Related]
22. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
23. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
24. Miltefosine-Lopinavir Combination Therapy Against
Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
[TBL] [Abstract][Full Text] [Related]
25. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
26. Miltefosine Combined with Intralesional Pentamidine for
Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
[TBL] [Abstract][Full Text] [Related]
28. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
Emiliano YSS; Almeida-Amaral EE
J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
[TBL] [Abstract][Full Text] [Related]
30. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes.
Miguel DC; Yokoyama-Yasunaka JK; Andreoli WK; Mortara RA; Uliana SR
J Antimicrob Chemother; 2007 Sep; 60(3):526-34. PubMed ID: 17584801
[TBL] [Abstract][Full Text] [Related]
32. Antileishmanial Activity of Pyrazolopyridine Derivatives and Their Potential as an Adjunct Therapy with Miltefosine.
Anand D; Yadav PK; Patel OP; Parmar N; Maurya RK; Vishwakarma P; Raju KS; Taneja I; Wahajuddin M; Kar S; Yadav PP
J Med Chem; 2017 Feb; 60(3):1041-1059. PubMed ID: 28059524
[TBL] [Abstract][Full Text] [Related]
33. Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
Cavalcanti de Queiroz A; Alves MA; Barreiro EJ; Lima LM; Alexandre-Moreira MS
Exp Parasitol; 2019 Jun; 201():57-66. PubMed ID: 31004571
[TBL] [Abstract][Full Text] [Related]
34. Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on Leishmania amazonensis.
Stroppa PHF; Antinarelli LMR; Carmo AML; Gameiro J; Coimbra ES; da Silva AD
Bioorg Med Chem; 2017 Jun; 25(12):3034-3045. PubMed ID: 28433512
[TBL] [Abstract][Full Text] [Related]
35. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
[TBL] [Abstract][Full Text] [Related]
36. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
37. Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool.
Reimão JQ; Trinconi CT; Yokoyama-Yasunaka JK; Miguel DC; Kalil SP; Uliana SR
J Microbiol Methods; 2013 May; 93(2):95-101. PubMed ID: 23466934
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis.
da Cunha-Júnior EF; Pacienza-Lima W; Ribeiro GA; Netto CD; do Canto-Cavalheiro MM; da Silva AJ; Costa PR; Rossi-Bergmann B; Torres-Santos EC
J Antimicrob Chemother; 2011 Jul; 66(7):1555-9. PubMed ID: 21531758
[TBL] [Abstract][Full Text] [Related]
39. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
